ALKS 7290 not checked

Alkermes, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Attention Deficit Disorder With Hyperactivity (ADHD), Major Depressive Disorder (MDD)
Main trialPhase 2
“The purpose of this study is to measure safety and the improvement in symptoms in subjects with ADHD when taking ALKS 7290 tablets compared with placebo tablets.”In the company’s words, NCT07755410 on ClinicalTrials.gov

Other drugs for Attention Deficit Disorder With Hyperactivity (ADHD)

All 5 drugs for Attention Deficit Disorder With Hyperactivity (ADHD)

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Jul 2027 A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
Phase 2Recruiting Jan 2028 A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ALKS 7290

Following is part of Solo: you see every change to ALKS 7290 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in